Berchuck A - Search Results

1

A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.

Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT, Rossing MA, Modugno F, Moysich KB, Chang-Claude J, Rudolph A, Gentry-Maharaj A, Terry KL, Gayther SA, Cramer DW, Doherty JA, Schildkraut JM, Kjaer SK, Ness RB, Menon U, Berchuck A, Mukherjee B, Roman L, Pharoah PD, Chenevix-Trench G, Olson S, Hogdall E, Wu AH, Pike MC, Stram DO, Pearce CL; Ovarian Cancer Association Consortium. Lee AW, et al. Among authors: berchuck a. Int J Cancer. 2016 Dec 15;139(12):2646-2654. doi: 10.1002/ijc.30274. Epub 2016 Sep 16. Int J Cancer. 2016. PMID: 27420401 Free PMC article.

2

Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.

Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Olt G, et al. Among authors: berchuck a. Cancer. 1992 Oct 15;70(8):2137-42. doi: 10.1002/1097-0142(19921015)70:8<2137::aid-cncr2820700821>3.0.co;2-w. Cancer. 1992. PMID: 1394043

3

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Schildkraut JM, et al. Among authors: berchuck a. Am J Obstet Gynecol. 1995 Mar;172(3):908-13. doi: 10.1016/0002-9378(95)90020-9. Am J Obstet Gynecol. 1995. PMID: 7892884

4

Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.

Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A. Hurteau J, et al. Among authors: berchuck a. Cancer. 1994 Jul 1;74(1):93-9. doi: 10.1002/1097-0142(19940701)74:1<93::aid-cncr2820740117>3.0.co;2-p. Cancer. 1994. PMID: 8004589

5

A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.

Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leech V, Molyneux A, Berchuck A, Ponder BA, et al. Jacobs IJ, et al. Among authors: berchuck a. Cancer Res. 1993 Mar 15;53(6):1218-21. Cancer Res. 1993. PMID: 8095178

6

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

7

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

Schildkraut JM, Bastos E, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. J Natl Cancer Inst. 1997 Jul 2;89(13):932-8. doi: 10.1093/jnci/89.13.932. J Natl Cancer Inst. 1997. PMID: 9214672

8

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

9

Managing hereditary ovarian cancer risk.

Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Berchuck A, et al. Cancer. 1999 Dec 1;86(11 Suppl):2517-24. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2517::aid-cncr8>3.0.co;2-b. Cancer. 1999. PMID: 10630177 Review.

10

Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.

Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. Obstet Gynecol. 2000 Jan;95(1):119-27. doi: 10.1016/s0029-7844(99)00535-9. Obstet Gynecol. 2000. PMID: 10636514

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

632 results

Search Page